Chemical Structure (Figure 01 Chemical Structure)
Betaxolol Hydrochloride Tablet, Coated
Product Images NDC 10702-014
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Betaxolol Hydrochloride (NDC 10702-014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Kvk-tech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Adverse Reactions (Figure 02 Table1)
Adverse Reactions (Figure 03 Table2)
This is a table of adverse reactions experienced by patients taking Betawohl Aenohl Placebo. The table shows the number of patients that experienced specific symptoms (such as Bredycardia, Symptomatic bradycardia, Palpitation, Edema, Cald extremities, Headache, Diziness, Fatigue, Asthenia, Insomnia, Paresthesia, Neusea, Dyspepsia, Diarthea, Chest pain, Joint pain, and Myalgia) during the study (N=155) (N=81) (N=60) (Dose range 20-40 mg, 100 mg).*
Kvk Logo (Figure 04 Logo)
10 mg Label (Figure 05 10mg Label)
This is a description for Betaxolol Tablets, USP that are marked with NDC 10702-013-01. It contains 10 mg potency of Betaxolol. The usual recommended adult dosage is one tablet every 24 hours. The tablets are meant to be dispensed in either a tight or light-resistant container with child-resistant closures as defined in the USP. Keep this medication out of the reach of children. The tablets are manufactured and distributed by KVK-Tech Inc., located in Newtown, PA 18940.*
20 mg Label (Figure 06 20mg Label)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
